Global Clostridium Difficile Treatment Market 2017-2021


◆タイトル:Global Clostridium Difficile Treatment Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥371,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥530,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Clostridium Defficile Treatment CDI is a bacterium that can cause symptoms such as diarrhea and life-threatening inflammation of the colon. CDI mostly affects elderly people who frequent hospitals or people who live in long-term care facilities. CDI can also occur due to the prolonged use of antibiotics. The first line of treatment for CDI is antibiotics.
Technavio’s analysts forecast the global clostridium defficile treatment market to grow at a CAGR of 5.14% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global clostridium defficile treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
· Americas
Technavio’s report, Global Clostridium Defficile Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
· Actelion Pharmaceuticals
· Merck
· Pfizer
· Summit Therapeutics

[Other prominent vendors]
· Astellas Pharma
· Da Volterra
· Immuron
· MGB Biopharma
· Novartis
· Otsuka Pharmaceutical
· Rebiotix
· Romark Laboratories
· Sanofi Pasteur
· Seres Therapeutics
· Shire
· Synthetic Biologics
· Valeant Pharmaceuticals
· Valneva

[Market driver]
• Rise in aging population
• For a full, detailed list, view our report

[Market challenge]
• High cost of therapy and high mortality rate
• For a full, detailed list, view our report

[Market trend]
• Special designation
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Overview

PART 05: Pipeline landscape

PART 06: Market landscape
• Overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by drug category
• Narrow spectrum antibiotic
• Broad spectrum antibiotics

PART 08: Geographical segmentation
• Americas

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Emergence of vaccines
• Special designation
• Drug candidates with strong MOA

PART 12: Vendor landscape
• Competitive scenario

PART 13: Key vendor analysis
• Actelion Pharmaceuticals
• Merck
• Pfizer
• Summit Therapeutics
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: CDI: Symptoms
Exhibit 02: Various causes of CDI
Exhibit 03: Global CDI treatment market: Key pipeline molecules by vendors 2016
Exhibit 04: Key clinical trials
Exhibit 05: Global CDI treatment market: Overview
Exhibit 06: Global CDI treatment market 2016-2021 ($ million)
Exhibit 07: Five forces analysis
Exhibit 08: Global CDI treatment market: Segmentation by drug category 2016
Exhibit 09: Global CDI narrow spectrum antibiotics market 2016-2021 ($ million)
Exhibit 10: Global CDI broad spectrum antibiotics market 2016-2021 ($ million)
Exhibit 11: Global CDI treatment market: Segmentation by geography 2016 and 2021 (% share)
Exhibit 12: Global CDI treatment market: Revenue by geography 2016-2021 ($ million)
Exhibit 13: Americas: Overview
Exhibit 14: CDI treatment market in Americas 2016-2021 ($ million)
Exhibit 15: EMEA: Overview
Exhibit 16: CDI treatment market in EMEA 2016-2021 ($ million)
Exhibit 17: APAC: Overview
Exhibit 18: CDI treatment market in APAC 2016-2021 ($ million)
Exhibit 19: Drugs under development
Exhibit 20: Vaccines in development stage
Exhibit 21: Companies that have benefited from special designations
Exhibit 22: Global CDI treatment market: Competitive structure analysis 2016
Exhibit 23: Global CDI treatment market: Strategic success factors of companies
Exhibit 24: Actelion: Key highlights
Exhibit 25: Actelion: Strength assessment
Exhibit 26: Actelion: Strategy assessment
Exhibit 27: Actelion: Opportunity assessment
Exhibit 28: Merck: Key highlights
Exhibit 29: Merck: Strength assessment
Exhibit 30: Merck: Strategy assessment
Exhibit 31: Merck: Opportunity assessment
Exhibit 32: Pfizer: Key highlights
Exhibit 33: Pfizer: Strength assessment
Exhibit 34: Pfizer: Strategy assessment
Exhibit 35: Pfizer: Opportunity assessment
Exhibit 36: Summit Therapeutics: Key highlights
Exhibit 37: Summit Therapeutics: Strength assessment
Exhibit 38: Summit Therapeutics: Strategy assessment
Exhibit 39: Summit Therapeutics: Opportunity assessment


Actelion Pharmaceuticals, Merck, Pfizer, and Summit Therapeutics



★調査レポート[クロストリジウムディフィシル感染症治療薬の世界市場] (Global Clostridium Difficile Treatment Market 2017-2021 / IRTNTR13373)販売に関する免責事項
[クロストリジウムディフィシル感染症治療薬の世界市場] (Global Clostridium Difficile Treatment Market 2017-2021 / IRTNTR13373)についてEメールでお問い合わせ